• 1
    Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y Zevalin (90yttrium ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 76677.
  • 2
    Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 18194.
  • 3
    Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15: 101725.
  • 4
    Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 142433.
  • 5
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 43545.
  • 6
    Kocher DC. Radioactive decay data tables: a handbook of decay data for application to radiation dosimetry and radiological assessments. USA: U.S. Department of Energy, 1981.
  • 7
    Gansow O. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 1991; 18: 36981.
  • 8
    Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793803.
  • 9
    Stabin M. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 53846.
  • 10
    Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations (revised edition). New York, NY: Society of Nuclear Medicine; 1991.
  • 11
    Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 68994.
  • 12
    Retzlaff J, Tauxe W, Kiely J, Stroebel C. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood 1969; 33: 64967.
  • 13
    Witzig TE, White CA, Gordon LI, et al. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood 2000; 96: 831a, [Abstract no. 3591].
  • 14
    Witzig TE, Gordon LI, Wiseman GA, et al. Reduced dose Zevalin is safe and effective in patients with relapsed or refractory, low grade, follicular or CD20+ transformed B cell non-Hodgkin's lymphoma (L/F/T NHL) and mild thrombocytopenia. Blood 2000; 96: 728a, [Abstract no. 3149].
  • 15
    Witzig TE, White CA, Flinn IW, et al. 90Y Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma. Blood 2000; 96: 507a, [Abstract no. 2183].
  • 16
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, et al. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000; 41: 9528.
  • 17
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5: 3292s3303s.
  • 18
    Wahl RL, Zasadny KS, Gates VR, et al. Patient dosimetry-individualized 131I anti-B-1 Mab lymphoma radioimmunotherapy: is it feasible in a multicenter trial? Immunol Biol Ther 1997; 16: 431a, [Abstract no. 1546].
  • 19
    Kostakoglu L, Leonard JP, Coleman M, et al. Extent of disease impacts the effective half-life of iodine-131 tositumomab in non-Hodgkin's lymphoma. Blood 1999; 94: 90a, [Abstract no. 391].